tranexamic acid has been researched along with Circulatory Collapse in 9 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This case reminds clinicians that perioperative tranexamic acid administration may increase the risk of thrombosis, which needs focused attention from anesthesiologists." | 8.02 | Circulation collapse caused by intracardiac thrombosis associated with tranexamic acid administration: A case report. ( Gu, KP; Huang, CJ; Xie, Q; Yao, YX, 2021) |
| " This study investigates whether out-of-hospital TXA use is associated with adverse events or unfavorable outcomes in suspected traumatic brain injury (TBI) when intracranial hemorrhage (ICH) is absent on initial computed tomography." | 7.11 | Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial. ( Dewey, EN; Harmer, JW; Meier, EN; Rowell, SE; Schreiber, MA, 2022) |
| "The current therapeutic strategy for disseminated intravascular coagulation (DIC) is limited to control of the underlying disease, and methods for the effective management of DIC have not been established." | 5.34 | Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. ( Asada, N; Asakura, H; Koseki, M; Matsue, K; Takeuchi, M; Uryu, H, 2007) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "This case reminds clinicians that perioperative tranexamic acid administration may increase the risk of thrombosis, which needs focused attention from anesthesiologists." | 4.02 | Circulation collapse caused by intracardiac thrombosis associated with tranexamic acid administration: A case report. ( Gu, KP; Huang, CJ; Xie, Q; Yao, YX, 2021) |
| " This study investigates whether out-of-hospital TXA use is associated with adverse events or unfavorable outcomes in suspected traumatic brain injury (TBI) when intracranial hemorrhage (ICH) is absent on initial computed tomography." | 3.11 | Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial. ( Dewey, EN; Harmer, JW; Meier, EN; Rowell, SE; Schreiber, MA, 2022) |
| "Postpartum hemorrhage is the number one cause of severe morbidity during hospitalization for birth, despite hospital, state, and national initiatives." | 2.72 | Goals for Collaborative Management of Obstetric Hemorrhage. ( Baird, SM; Kennedy, MBB; Martin, S, 2021) |
| "The current therapeutic strategy for disseminated intravascular coagulation (DIC) is limited to control of the underlying disease, and methods for the effective management of DIC have not been established." | 1.34 | Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. ( Asada, N; Asakura, H; Koseki, M; Matsue, K; Takeuchi, M; Uryu, H, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Q | 1 |
| Huang, CJ | 1 |
| Gu, KP | 1 |
| Yao, YX | 1 |
| Harmer, JW | 1 |
| Dewey, EN | 1 |
| Meier, EN | 1 |
| Rowell, SE | 1 |
| Schreiber, MA | 1 |
| Baird, SM | 1 |
| Martin, S | 1 |
| Kennedy, MBB | 1 |
| DeLano, FA | 1 |
| Chow, J | 1 |
| Schmid-Schönbein, GW | 1 |
| Reyes-Chicuellar, N | 1 |
| Doddi, NM | 1 |
| Kalro, A | 1 |
| Patel, H | 1 |
| Martínez Rodríguez, E | 1 |
| Mato, M | 1 |
| Otero, J | 1 |
| Ferri, JR | 1 |
| Gonzálvez, A | 1 |
| Torres, LM | 1 |
| Koseki, M | 1 |
| Asada, N | 1 |
| Uryu, H | 1 |
| Takeuchi, M | 1 |
| Asakura, H | 1 |
| Matsue, K | 1 |
| Verstraete, M | 1 |
| Bottari, M | 1 |
| Donati, L | 1 |
| Gagnatelli, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prehospital Tranexamic Acid Use for Traumatic Brain Injury[NCT01990768] | Phase 2 | 967 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death). (NCT01990768)
Timeframe: 6 months post-injury
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 8.0 |
| Bolus-Maintenance | 8.1 |
| Bolus Only | 6.6 |
The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death). (NCT01990768)
Timeframe: At the end of the hospital stay (average of 9 days post injury)
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 9.0 |
| Bolus-Maintenance | 9.4 |
| Bolus Only | 8.1 |
Hospital-free days count any day from hospital admission through day 28 that the patient is alive and out of the hospital. (NCT01990768)
Timeframe: From hospital admission through day 28
| Intervention | days (Mean) |
|---|---|
| Placebo | 13.6 |
| Bolus-Maintenance | 13.6 |
| Bolus Only | 14.1 |
ICU-free days count any day from hospital admission through day 28 that the patient is alive and not in the ICU. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0. (NCT01990768)
Timeframe: From hospital admission through day 28
| Intervention | days (Mean) |
|---|---|
| Placebo | 18.5 |
| Bolus-Maintenance | 18.1 |
| Bolus Only | 19.1 |
The counts of patients who died on or before day 28 are reported. (NCT01990768)
Timeframe: 28 days after hospital arrival
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 50 |
| Bolus-Maintenance | 53 |
| Bolus Only | 40 |
Diagnosis of one or more of the following: cerebral ischemic event, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), or any other thromboembolic event (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 30 |
| Bolus-Maintenance | 13 |
| Bolus Only | 31 |
Diagnosis of cerebral ischemic event (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 10 |
| Bolus-Maintenance | 3 |
| Bolus Only | 13 |
Diagnosis of DVT (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Bolus-Maintenance | 3 |
| Bolus Only | 10 |
All clinically indicated head computed tomography (CT) scans obtained during the initial hospitalization or within the first 28 days were assessed for ICH. Parenchymal (IPH), subdural (SDH) and epidural (EDH) hemorrhage volumes were measured and quantified using volumetric software and verified by manual calculations based on the previously validated ABC/2 technique. The sum of the IPH, SDH, and EDH volumes were compared across scans. A relative increase of 33% (and at least a 1 ml increase) on any subsequent scan compared to the initial scan was defined as a progression. (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 13 days among patients with multiple scans)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 30 |
| Bolus-Maintenance | 26 |
| Bolus Only | 27 |
Diagnosis of an acute myocardial infarction (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 1 |
| Bolus-Maintenance | 3 |
| Bolus Only | 2 |
Neurosurgical interventions include craniotomy, craniectomy, and placement of a neuromonitoring or drainage device. Counts are of subjects with one or more neurosurgical interventions. (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 54 |
| Bolus-Maintenance | 62 |
| Bolus Only | 75 |
Diagnosis of PE (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| Bolus-Maintenance | 3 |
| Bolus Only | 6 |
Seizures may cause involuntary changes in body movement or function, sensation, awareness, or behavior. Seizures are often associated with a sudden and involuntary contraction of a group of muscles and loss of consciousness. Seizures or episodes of seizure-like activity were reported by medics in the field following the start of study drug infusion through hand-off to the trauma center and by trauma center staff through discharge. Reported events were included if providers gave anti-seizure medication and/or the event was confirmed by EEG. (NCT01990768)
Timeframe: From start of study drug infusion through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 7 |
| Bolus-Maintenance | 5 |
| Bolus Only | 17 |
GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. The number of subjects with unfavorable outcome is reported. (NCT01990768)
Timeframe: At the end of the hospital stay (average of 9 days post injury)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 196 |
| Bolus-Maintenance | 193 |
| Bolus Only | 228 |
Ventilator-free days count any day from hospital admission through day 28 that the patient is alive and does not require mechanical ventilatory support. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0. (NCT01990768)
Timeframe: From hospital admission through day 28
| Intervention | days (Mean) |
|---|---|
| Placebo | 20.2 |
| Bolus-Maintenance | 19.9 |
| Bolus Only | 20.9 |
2 reviews available for tranexamic acid and Circulatory Collapse
| Article | Year |
|---|---|
Goals for Collaborative Management of Obstetric Hemorrhage.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Goals; Humans; Hysterectomy; Maternal Mortality; | 2021 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
1 trial available for tranexamic acid and Circulatory Collapse
| Article | Year |
|---|---|
Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Retrospective Studies; Shock; Tomography | 2022 |
6 other studies available for tranexamic acid and Circulatory Collapse
| Article | Year |
|---|---|
Circulation collapse caused by intracardiac thrombosis associated with tranexamic acid administration: A case report.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Circulation; Blood Loss, Surgical; C | 2021 |
Volatile Decay Products in Breath During Peritonitis Shock are Attenuated by Enteral Blockade of Pancreatic Digestive Proteases.
Topics: Animals; Chromatography, Gas; Intestinal Mucosa; Methylamines; Peptide Hydrolases; Peritoneum; Perit | 2017 |
Sphenopalatine Artery Ligation for Life-Threatening Epistaxis in a 4-Year-Old Child With Glanzmann Thrombasthenia.
Topics: Antifibrinolytic Agents; Child, Preschool; Endoscopy; Epistaxis; Factor VIIa; Female; Fluid Therapy; | 2019 |
[Hemostatic drugs in a patient with antiphospholipid syndrome and clinically significant perioperative bleeding].
Topics: Adult; Aminocaproic Acid; Antiphospholipid Syndrome; Aprotinin; Blood Coagulation Tests; Blood Loss, | 2006 |
Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis.
Topics: Acute Disease; Adult; alpha-2-Antiplasmin; Antifibrinolytic Agents; Antineoplastic Agents; Antithrom | 2007 |
[Disseminated intravascular coagulation as a complication of shock].
Topics: Aminocaproic Acid; Aprotinin; Disseminated Intravascular Coagulation; Heparin; Humans; Shock; Tranex | 1973 |